Kirin Holdings Company (2503) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
Q1 FY2025 revenue rose 8.8% year-over-year to 545.9 bn yen, driven by strong Alcoholic Beverages and Health Science segments, including FANCL's contribution.
Normalized operating profit increased 9.9% to 36.3 bn yen, but profit attributable to owners fell 6.0% to 24.3 bn yen due to FX and absence of prior year one-time gains.
EPS decreased 6.0% year-over-year to 30 yen.
Financial highlights
Revenue: 545.9 bn yen (+8.8% YoY); Normalized OP: 36.3 bn yen (+9.9% YoY); Profit before tax: 38.3 bn yen (-13.4% YoY); Net profit: 24.3 bn yen (-6.0% YoY).
Gross profit up 10.9% YoY to 253.6 bn yen; normalized EBITDA up 13.7% to 62.7 bn yen.
Cash flow from operating activities: 10.2 bn yen, down 29.6 bn yen YoY; free cash flow: -35.2 bn yen.
Total assets: 3,259.1 bn yen, down 95.1 bn yen from Q4 FY2024; total equity: 1,385.9 bn yen, down 147.8 bn yen, mainly due to FANCL acquisition and FX effects.
Operating profit was flat at 31.0 bn yen (+0.5% YoY); profit before tax declined 13.4% to 38.3 bn yen.
Outlook and guidance
FY2025 revenue forecast at 2,440 bn yen (+4.3% YoY); normalized operating profit 212 bn yen (+0.5% YoY); profit attributable to owners 150 bn yen (+157.7% YoY).
Full-year EPS forecast at 185.20 yen; annual dividend forecast raised to 74.00 yen per share.
Minor impact from US reciprocal tariffs expected in Q1 FY2025; future impact depends on evolving US policy but not anticipated to be significant.
Monitoring potential risks from raw material and packaging costs, with plans to manage through pricing and cost controls.
Latest events from Kirin Holdings Company
- Profit more than doubled, Health Science turned profitable, and major portfolio moves were made.2503
Q4 202513 Feb 2026 - Targets high single-digit EPS growth, ROIC ≥10%, and 3 trillion yen market cap by 2035.2503
Investor presentation13 Feb 2026 - Double-digit revenue and profit growth, but profit guidance trimmed on higher taxes.2503
Q2 202425 Jan 2026 - Profit and revenue up, FANCL fully consolidated, Health Science segment surges.2503
Q3 202511 Nov 2025 - Revenue rose 3.7% YoY, but profit and EPS fell on restructuring and FX impacts.2503
Q2 20257 Aug 2025 - Revenue and operating profit rose, but net profit dropped on FANCL acquisition loss.2503
Q3 202413 Jun 2025 - FY2025 profit is set to rebound sharply, driven by Health Science and Alcoholic Beverages.2503
Q4 20245 Jun 2025